Endocrine Abstracts

IntroductionWomen with Turner Syndrome (TS), characterised by the complete or partial absence of one X-chromosome in females, are reported to have an increased risk of coeliac disease, inflammatory bowel disease and angiodysplasia. These may contribute to iron deficiency and anaemia through malabsorption or blood loss. This study screened the serum ferritin and haemoglobin measurements in an adult TS population.MethodSerum ferritin concentrations were measured in 1...

Fetal exposure to environmental estrogens may contribute to hypofertility and/or to testicular germ cell cancer. However, many of these endocrine disruptors have only a weak affinity for the classical ERs and other mechanisms have been suggested. Bisphenol A, a chemical poluttant, used as monomer to manufacture polycarbonate plastic, released from lining canned food or beverages or from dental sealants, was able to promote human testicular seminoma cell (JKT-1) proliferation <...

G R Williams, Imperial College London, London, UK. AbstractGraham R Williams obtained a BSc in Anatomy and MBBS from St Thomas’s Hospital, London and undertook PhD studies in Molecular Endocrinology at Birmingham University. He trained as a Howard Hughes and MRC Fellow at Harvard Medical School, USA and was an MRC Clinician Scientist Fellow in Birmingham. He was appointed Senior Lecturer at the Royal Postgraduate...

Desmond G Johnston, Campus Dean, St Mary’s Hospital Campus, Imperial College London, London, UK Director, UK Diabetes Research Network AbstractProfessor Johnston trained in Edinburgh and Southampton where, as an MRC Training Fellow, he did his PhD with Professor George Alberti. His work at that time investigated metabolic disturbances in liver disease and metabolic aspects of endocrinology.I...

Ron G Rosenfeld, Lucile Packard Foundation for Children's Health, Stanford University, Palo Alto, CA., USA. AbstractRon G Rosenfeld, MD, is the Senior Vice-President for Medical Affairs at the Lucile Packard Foundation for Children's Health at Stanford University. He is Professor of Pediatrics at Stanford University, as well as Professor and Chair (emeritus) of Pediatrics and of Cell and Developmental Biology at Oregon...

Orexin-A and orexin-B orchestrate their diverse central and peripheral effects via two G-protein coupled receptors, OX1R and OX2R, which activate multiple G-proteins. They are involved in a host of physiological processes including, steroidogenesis, appetite control and energy regulation. Whilst some signalling mechanisms have been proposed for individual recombinant orexin receptors in generic mammalian cell types, it is clear that the peripheral effects of orexin are spatial...

The glycoprotein hormone, TSH, is synthesized and secreted by thyrotrophs in the anterior pituitary gland. It acts at the TSH receptor (TSHR), a 7-transmembrane G-protein coupled cell membrane receptor expressed in thyroid follicular cells. The TSHR, thus, plays a key role in the regulation of thyroid status and growth of the thyroid gland. In recent years TSHR expression has also been identified in a wide variety of extra-thyroidal tissues including: anterior pituitary; hypot...

Background & Aims: ATP binding cassette subfamily G1 (ABCG1) is involved in mediating cholesterol efflux and modulating cellular lipid homeostasis. It is influenced by endogenous glucose and our aim was to examine the relationship between ABCG1 expression and lipid profiles within the increased glucose levels of subjects with Type 2 diabetes (ODM).Methods: RNA was extracted from visceral fat collected from subjects undergoing abdominal surgery (baria...

Hypoparathyroidism is a disorder of mineral homoeostasis due to parathyroid hormone (PTH) deficiency. Conventional treatment with oral Ca and calcitriol may maintain serum Ca levels but does not replace other physiologic PTH effects. RACE is an ongoing open-label study of recombinant human PTH1-84 (rhPTH1-84) for hypoparathyroidism treatment in adults (ClinicalTrials.gov NCT01297309). Patients initially received rhPTH1-84 25 or 50 μg/day subcutaneously, with 25-μg in...

Background: TPTD treatment has been shown to reduce vertebral and non-vertebral fracture risk in postmenopausal osteoporosis efficiently. However, gains in bone mass achieved by this treatment are almost lost 2 years after cessation of treatment, unless consecutively followed by an antiresorptive treatment such as alendronate.Subjects and methods: In the present prospective randomised open-labelled study in 52 pmp women, we investigated the effect of eit...